Catalog No.
RHD10802
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P15391
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1246
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies., PMID:40463123
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Nanobody-Directed CEA-targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts., PMID:40439687
Modular cell line for scalable and rapid in vitro evaluation of chimeric antigen receptors., PMID:40374131
An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734
Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs., PMID:39976474
Novel Immunotherapy Targets for Relapsed/Refractory B-ALL: A Literature Review., PMID:39222522
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells., PMID:39054481
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms., PMID:38960449
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311
Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display., PMID:38066569
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies., PMID:38007238
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts., PMID:36875091
Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory., PMID:36267609
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL., PMID:35981465
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia., PMID:35051588
A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity., PMID:34830793
Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival., PMID:34722633
Topological and Structural Plasticity of the Single Ig Fold and the Double Ig Fold Present in CD19., PMID:34572502
Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells., PMID:34500284
Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells., PMID:34429118
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC., PMID:33999642
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3., PMID:33992682
Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL., PMID:33727310
[Construction of camelidae natural nanobody phage dispaly library and screening, production and identification of anti-CD19 nanobody]., PMID:33210599
Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy., PMID:32964055
Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds., PMID:32794303
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia., PMID:31951650
CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs., PMID:31004624
Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes., PMID:29922424
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors., PMID:27548616
For research use only. Not for human or drug use.
